Migraine: Diagnosis and current management options

Smit JA, MBChB, MMed(Neu)
Private Neurologist, The Willows Hospital, Pretoria-East

INTRODUCTION

Half of the population experiences headaches at least once a month, 15% once a week and 5% of patients have headaches every day of their lives. The lifetime prevalence of migraine is approximately 19% for women and 6% for men, thus accounting for a large proportion of patients suffering from headache. Females around the age of 40 have the highest prevalence (24%) of migraine. The mean frequency of migraine attacks is 1.5 attacks per month, but it is important to stress that at least 10% of patients suffering from migraine will have one attack per week. Migraine is therefore a major cause of time lost from work and resulting medical expenses due to headaches.

DIAGNOSIS OF MIGRAINE

The International Headache Society’s classification of headache disorders has made the diagnosis of migraine and other headache syndromes considerably easier. The essential diagnostic elements of migraine according to this classification are summarised in Table 1.

Migraine diagnosis starts with a carefully taken history. This is important because the headaches are classified according to their clinical presentation. It is possible that a patient can have concurrent headache types, for instance migraine, as well as tension type headaches. The headache history should then be analysed for the characteristic elements of migraine, which can be differentiated in four separate stages:

The prodrome
This occurs hours to days before the onset of headache in approximately 60% of migraineurs. This usually consists of non-specific symptoms, including depression, euphoria, irritability, photophobia, phonophobia and hypersomnia.

The migraine aura
Only 30% of migraine headaches are associated with aura. These are focal neurological phenomena that precede or accompany the headache attack, always clearing up fully during the course of a migraine episode. Visual symptoms are by far the most common (99% of all auras). Other sensory changes including aphasia and, rarely, paralysis can however, be part of an aura phenomenon. The same patient may have migraine headache with and without aura and also auras without headache.

Headache
Migraine headache is typically a unilateral throbbing headache with moderate to incapacitating pain-severity aggravated by routine physical activity. In clinical practice patients often present with either a unilateral or a severe, but not throbbing headache, which still is migraine. Migraine can occur anytime of day or night, frequently upon rising.

(Continued on page 34)

| Table 1: The simplified diagnostic criteria of migraine

<table>
<thead>
<tr>
<th>Simplified diagnostic criteria for migraine with and without aura adapted from the International Headache Society’s Classification – 1998.</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Attacks lasting 4 to 72 hours.</td>
</tr>
<tr>
<td>• At least two of the following four headache characteristics – unilateral, pulsating, moderate to severe, aggravated by movement.</td>
</tr>
<tr>
<td>• At least one of the associated symptoms – nausea or vomiting, photophobia, phonophobia.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Migraine with aura:</th>
</tr>
</thead>
<tbody>
<tr>
<td>• One or more transient focal neurological aura symptom.</td>
</tr>
<tr>
<td>• Gradual development of aura symptoms over more than four minutes, or several symptoms in succession.</td>
</tr>
<tr>
<td>• All the symptoms last 4 to 60 minutes.</td>
</tr>
<tr>
<td>• Headache follows or accompanies aura within 60 minutes.</td>
</tr>
</tbody>
</table>
which can cause a return of the headache after treatment. They can aggravate nausea and vomiting and carry the risk of causing dependency if used frequently. The frequent use of drugs containing codeine also has the risk of causing rebound headaches.  

Specific anti-migraine treatment
These drugs are aimed specifically at stopping the acute attack of migraine, but do not have any analgesic properties themselves. There are two broad classes: ergotamine and its related compounds, and the triptans (5HT1B and D receptor agonists).

The discovery of the triptans gave an effective alternative therapeutic approach to the management of acute migraine and has become the drug of choice for moderate to severe attacks.

Sumatriptan was the first of this class to be developed and is also the most extensively studied medication. Unfavourable oral bio-availability and the relatively short half-life of Sumatriptan inspired the search for compounds that possess superior pharmocokinetic characteristics. A number of second generation agents, including Zolmitriptan, Naratriptan, Rizatriptan and Eritriptan have subsequently come to the market, all possessing certain advantages over Sumatriptan. Sumatriptan remains the only triptan available in an injectable formulation, as well as a nasal spray, but both Rizatriptan and Zolmitriptan are available in a rapidly dissolving formulation, which can be taken without water. These drugs are highly effective; in all the triptan studies where these drugs were compared to placebo, the headache-free data at 2 hours, were statistically far superior when compared to placebo treated patients. The most frequently reported adverse events with this class of medication include dizziness, nausea, asthena, chest symptoms and paresthesias. These side effects are, however, usually relatively mild and do not occur very frequently. Triptans do possess the ability to constrict human coronary arteries at therapeutic doses. Because of this potential risk and due to rare reports of serious cardiac events, all triptans are contra-indicated in patients with coronary artery disease and uncontrolled hypertension.  

Triptans can, however, be safely used by the great majority of migraine patients.

It can also be said that if the diagnosis of migraine were made in a patient it would be an unacceptable medical practice not to prescribe a triptan as part of the acute management of the attacks unless specifically contra-indicated.

Preventative treatment
The goal of preventative treatment should be to prevent or reduce the frequency of migraine attacks and to improve response to acute medications when an acute attack does occur.

Preventive treatment should be instituted when:
- Migraine has a substantial impact on a patient’s life, despite the use of acute medications.
- If acute medication fails to provide relief.
- High attack frequency.
- Where there are contra-indications, negatively affecting the use of successful acute medication.
- Where there is overuse of acute medication.

Many drugs have been reported to be effective in migraine prophylaxis. The mechanism of action of these drugs is varied and no single medication has emerged as a clearly dominant treatment. Prophylactic drugs can be divided into different classes. (Table 4)

The choice of a prophylactic agent is often difficult and should be tailored to the needs of a specific patient. For instance, if there is hypertension or a cardiovascular disorder, a beta-blocker may be a good choice, but in the instance of asthma, a beta-blocker would be contra-indicated. When there is depression or bipolar dysfunction, the use of antidepressants or anticonvulsants may be a reasonable choice. In an obese patient the use of Valproic acid and Tricyclic antidepressants may be a poor choice, while Topiramate, which may induce weight loss can be helpful.

The general principal would be that, whatever prophylactic agent is selected, the drug should be started at a low dose and increased slowly until therapeutic effects develop, the ceiling dose for the chosen drug is reached, or if side effects become intolerable. Migraine prevention often requires a lower dose of medication than that needed for other indications. A specific treatment regimen should be given an adequate therapeutic trial of 2 to 6 months and then re-evaluated. If ineffective, alternative treatment options should be tried, but if the patient re-sponds very well, it may be reasonable to slowly taper and discontinue therapy. It is advisable to avoid prophylactic agents during pregnancy due to risks to mother and unborn child. Patients should be involved in the decision-making with regard to the preferred drug for the management of the headaches.

CONCLUSION
Migraine management with Triptans and prophylactic medication, when indicated, offer greatly improved quality of life to the majority of migraine sufferers. Treatment, however, starts with an accurate diagnosis.

Please refer to the CPD Questionnaire on page 51.

References
3. Hewitt WF, Schechter A, Russo-Rowlinson BK. (Continued on page 38)

Table 4: Classes of preventative migraine drugs

<table>
<thead>
<tr>
<th>Anti-convulsants:</th>
<th>Valproate, Topiramate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-depressants:</td>
<td>Tricyclic anti-depressants, SSRI's</td>
</tr>
<tr>
<td>Beta-blockers:</td>
<td>Propranolol and Atenolol</td>
</tr>
<tr>
<td>Calcium channel antagonists:</td>
<td>Verapamil</td>
</tr>
<tr>
<td>Serotonin antagonists:</td>
<td>Methysergide</td>
</tr>
<tr>
<td>Others:</td>
<td>NSAID's, Clonidine, Botulinum toxin, Riboflavin, Magnesium, Neuroleptics</td>
</tr>
</tbody>
</table>
Advertorial

Valuable financial support from Thom Kight and Company for Wits University’s School of Anatomical Sciences

Johannesburg – Operating from Vrededorp, Johannesburg, Thom Kight and Company, a company providing funeral services, has come to the aid of Wits University’s Faculty of Health Sciences. Through a substantial financial donation, Thom Kight and Company provides vital funding to further the development of medical research at Wits University’s School of Anatomical Sciences.

“Much like our own philosophy, Wits University is committed to the advancement of medical research through the maintenance of this important department within the university,” Says Thom Kight, Managing Director, Thom Kight and Company (Pty) Ltd. “Through continuous research provided by the School of Anatomical Sciences, advancement in medicine is possible,” continues Kight, “Our assistance in providing funding for the valuable Raymond Dart Collection goes beyond the financial assistance needed by the university, but is our commitment to the development of scientific and medical research aimed at improving the health and lifestyles of men and women”.

The Raymond Dart Collection of Human Skeletons is housed in the School of Anatomical Sciences in the Faculty of Health Sciences at the University of the Witwatersrand in Johannesburg, South Africa. This collection owes its inception to Raymond A. Dart, who was inspired during visits to the institutions housing the Wingate Todd and Terry collections in the United States.

Collections of modern human skeletal materials are important sources of information for research and clinical training in fields such as human variation, growth, palaeoanthropology, forensic science and various fields of surgery (e.g., Giraud, et al. 1984; Tobias, 1991).

Dr. Kevin Kuykendall, PhD, senior lecturer at the school says, “Most of the skeletons housed in the School of Anatomical Sciences are collected under provision of South Africa’s Human Tissues Act (No. 65 of 1983), and by previous Acts, e.g., the Anatomy Act, (No. 20 of 1959). Theses skeletons are used for dissection in teaching human anatomy courses at the University’s Medical School. At present, the majority of the human skeletal materials incorporated into the collection are obtained through bequestment to the School, though in the past, many of the remains in the Dart Collection represented unclaimed bodies from Gauteng (previously Transvaal) Provincial hospitals and other sources such as archaeological materials.” Dr Kuykendall adds, “The funding provided by companies like Thom Kight and Company certainly provides much needed support for our research facility.”

The complete collection catalogue records approximately 4000 human skeletons from a variety of sources, with new skeletal material being added annually from cadavers utilised in teaching.

“Much of the research findings arising from studying the Raymond Dart Collection will assist us in our daily operations as well,” concludes Thom Kight, “We are able to better understand the human body and be in a position to provide our clients with informed answers.”

For more information, please contact:
PUBLICITE, on behalf of Thom Kight and Company
Tel: (011) 791 5904, Fax: (011) 793 3142

SA Fam Pract 2003;45(8)